Scinai Immunotherapeutics
(NASDAQ) BVXV
Scinai Immunotherapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$7.78M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
BVXV News
BVXV: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Scinai Immunotherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
31
CEO
Amir Reichman, MBA
Website
www.scinai.comHeadquarters
Jerusalem, IL
BVXV Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-5%
Return on Capital
-45%
Return on Assets
-2%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$11.06M
EBITDA
$10.50M
Operating Cash Flow
$7.26M
Capital Expenditure
$836.00K
Free Cash Flow
$8.10M
Cash & ST Invst.
$14.07M
Total Debt
$21.54M
Scinai Immunotherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
33
N/A
Net Income
$3.76M
+70.7%
EBITDA
$2.60M
+69.2%
Quarterly Fundamentals
Net Cash
$17.11M
+54.4%
Accounts Receivable
$138.00K
-78.0%
Inventory
$0.00
N/A
Long Term Debt
$24.22M
-57.9%
Short Term Debt
$394.00K
-98.0%
Return on Assets
-1.96%
N/A
Return on Invested Capital
-44.73%
N/A
Free Cash Flow
$3.25M
-100.1%
Operating Cash Flow
$2.88M
-160.3%